ZimVie Inc.: directors' dealings · United States · SEC (Form 4)

About ZimVie Inc.

ZimVie Inc. is a U.S.-based medical device company that was listed on the Nasdaq in the United States. The company was formed in March 2022 as an independent public spin-off from Zimmer Biomet, bringing together the former Dental and Spine businesses under a standalone structure. ZimVie is headquartered in Palm Beach Gardens, Florida, and has historically served customers in more than 70 countries through a global commercial footprint and additional facilities around the world. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) In terms of business lines, ZimVie has been best known for dental implantology and restorative dentistry solutions. Its portfolio includes dental implants, prosthetic components, healing abutments, biomaterials, and digital workflow solutions used by dental professionals, implant surgeons, labs, and distributors. The company’s products are positioned around tooth replacement and restoration procedures, with a strong emphasis on clinically supported, differentiated platforms. ZimVie also had a spine business in its early post-spin-off years, but that segment was sold and closed in April 2024, leaving the company more tightly focused on dental. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-report-fourth-quarter-and-full-year-2024-financial/?utm_source=openai)) From a competitive standpoint, ZimVie operates as a specialized player in a global market that is populated by large, well-capitalized competitors. Its investment case has therefore centered on product differentiation, clinical evidence, international distribution, and portfolio focus rather than scale alone. After the spine divestiture, management emphasized a leaner structure and greater concentration of capital and attention on the dental franchise. That strategic reset is important for equity investors because it makes ZimVie a more focused dental company than the broader musculoskeletal and dental platform it once was. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-closing-sale-spine-business?utm_source=openai)) Recent corporate news was especially significant. In July 2025, ZimVie announced a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash. In October 2025, stockholders approved the transaction, and ZimVie later announced that the acquisition had been completed, after which the company became privately held. For market participants tracking ZIMV on the Nasdaq, this was the defining event of the period and materially changed the company’s public-market status, ownership structure, and strategic outlook. ([investor.zimvie.com](https://investor.zimvie.com/news-releases/news-release-details/zimvie-announces-definitive-agreement-be-acquired-archimed-1900?utm_source=openai))